Diligence memo · auto-generated · as of July 2, 2026

Interpace Diagnostics Group, Inc.

Interpace Diagnostics Group, Inc. has raised $113M over 5 rounds; too few niche peers to rank its valuation yet.

Diligence furtherNo decisive signal either way from the public record alone — the call needs primary diligence beyond the filings.

Businessfiled

Interpace Diagnostics Group, Inc. operates in Medical Devices, based in PARSIPPANY.

Sub-sector tags: medical-devices.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Interpace Diagnostics Group, Inc. has raised $113M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).

Largest single filing: $47M on 2020-01-10.

Most recent recorded round closed around 2024-10-11.

Valuation (modeled)modeled

Provath models Interpace Diagnostics Group, Inc. at approximately $365M (range $164M–$534M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Too few comparable companies in this niche to rank the valuation fairly yet.

Financing rhythm & timingmixed

Historic cadence: a new round about every 23 months.

Last raise 21 mo ago; this sector typically re-raises about every 16 months.

Slightly overdue versus sector cadence.

The last round stepped up 1.0× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 98% of Medical Devices peers (233 compared).

Modeled value ranks above 95% of those peers.

Closest niche peers: Digital Diagnostics Inc., Redcliffe Lifetech Inc, ACTIV Surgical, Inc..

Peoplefiled

18 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.